Key result
Rivaroxaban treatment in a hematology unit was associated with high persistence (2.5% discontinuation) and low rates of thromboembolic events (1.1 per 100 patient-years) over 1.8 years.
Why the study?
The study was conducted to determine drug persistence and rates of events among patients treated with rivaroxaban in a hematology unit.
Cohort (n=161)
No
In a real-world hematology unit setting, rivaroxaban therapy demonstrated high patient persistence and low rates of thromboembolic and bleeding events.
Supports rivaroxaban persistence in hematology units; hypothesis-generating and requires randomized confirmation before practice change.
Aim: To determine drug persistence and rates of events among patients treated with rivaroxaban in a hematology unit. Methods: Retrospective study of patients that started treatment with rivaroxaban, in the hematology unit of a tertiary hospital. Results: A total of 161 patients were included, of whom 83.9% had atrial fibrillation and 11.2% venous thromboembolism, and 76.4% of patients were taking rivaroxaban 20 mg, 22.4% 15 mg and 1.2% 10 mg. After a follow-up of 1.8 ± 1.1 years, only four patients (2.5%) discontinued treatment. Rates of thromboembolic events, major bleeding/clinically relevant nonmajor bleeding and intracranial hemorrhage were 1.1, 2.8, 0.3 events per 100 patient-years, respectively. Conclusion: In patients attended in a hematology unit, medication persistence was high, and the incidence of outcomes low.
No takes yet. Share an insight, caveat, or question.
Sebastián et al. (2019) conducted a cohort in Atrial fibrillation and venous thromboembolism (n=161). Rivaroxaban was evaluated on Drug persistence (treatment discontinuation). Rivaroxaban treatment in a hematology unit was associated with high persistence (2.5% discontinuation) and low rates of thromboembolic events (1.1 per 100 patient-years) over 1.8 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: